Research brief
Guardant Health closed at $131.60 for the week ended 12 June 2026, up 4.8%, with its Trend Signal active again after several inactive weeks. The stock has gained 38.7% over four weeks and 54.5% over 12 weeks, far outpacing Healthcare and Diagnostics & Research averages. The setup remains constructive, but a 169.0% premium to Fair Value, a 29.1% position above the Trend Line and below-average volume leave confirmation risk in view.
- Latest close was $131.60, only 2.0% below the 52-week high of $134.30 and at 97.2% of the yearly range.
- Momentum remains strong, with gains of 4.8% over one week, 38.7% over four weeks, 54.5% over 12 weeks and 167.0% over 52 weeks.
- The Trend Signal is active with a one-week streak, while Market Dynamics is positive at 1.11 but does not show a fresh buy state.
- Volume was 9.3M shares, equal to 0.9x the 13-week average and 0.8x the 52-week average, which tempers the confirmation.
- Guardant ranks in the upper quartile of US Healthcare by relative performance, but the stock trades 169.0% above Fair Value and 29.1% above its Trend Line.
A near-high close with a fresh signal restart
Guardant Health ended the week at $131.60, up 4.8%, as the precision-oncology testing company moved back to within 2.0% of its 52-week high. The move follows a volatile but powerful month: the stock rose 25.3% in the week of 22 May, added 9.0% on 29 May, dipped 3.1% on 5 June and then recovered this week. That sequence leaves the four-week return at 38.7% and the 12-week return at 54.5%.
The Sharemaestro Trend Signal is active again after being off for the prior stretch, with price 29.1% above the $102.00 Trend Line. Trend breadth is also supportive at 76.9%, or 40 active weeks out of the past 52. Market Dynamics improved to 1.11 and Relative Strength stands at 32.60, but the Market Dynamics state is still classed as no fresh buy, with the expectation reading undecided at 48.86%.
Healthcare context favours GH, diagnostics breadth is narrower
The sector backdrop is constructive but not uniformly strong. US Healthcare averaged a 0.8% weekly gain, 3.5% over four weeks and 7.9% over 12 weeks, while only 33.0% of the sector group showed active trend breadth. Against that, Guardant’s 4.8% weekly rise ranked 12th in the Healthcare group, and its four-week performance ranked first in the supplied sector set.
The industry comparison is even sharper. US Diagnostics & Research averaged a 1.7% weekly decline, with 20.0% trend breadth, 64.0% positive Market Dynamics breadth and only 24.0% positive Relative Strength breadth. Guardant ranked eighth for the week, fifth over four weeks and third over 12 weeks within the industry group. Twist Bioscience posted a stronger 10.0% weekly gain and 54.9% four-week return, while GeneDx rose 14.8% on the week, but Guardant’s active Trend Signal and positive Market Dynamics put it among the cleaner momentum profiles in the group.
Volume and valuation stretch keep the evidence mixed
The main qualification is participation. Weekly volume was 9.3M shares, below the 13-week average of 10.5M and the 52-week average of 11.2M. The resulting 0.9x 13-week volume ratio is not weak enough to contradict the move, but it falls short of the heavier confirmation normally associated with a decisive near-high advance.
Valuation distance is also elevated. Guardant trades 169.0% above Sharemaestro Fair Value of $48.93, while the latest price is 29.1% above the Trend Line. That premium reflects strong demand for the stock, but it raises the bar for continuation. Risk measures remain lively, with 13-week volatility at 9.8% versus 9.0% over 52 weeks, 25 downside weeks against 27 upside weeks, average gains of 8.4% and average losses of 4.3%.
What to watch next
The first watch point is whether the stock can hold its position near the top of the range without losing Market Dynamics support. A clean push through the $134.30 52-week high would carry more weight if volume rises meaningfully above the current 0.9x ratio, with 1.5x participation a clearer sign of broader sponsorship.
The second is the $102.00 Trend Line, which remains the key weekly regime level. A routine pause above that line would be consistent with consolidation after a 38.7% month. A sharper reversal with fading Market Dynamics would suggest the Fair Value premium and near-high positioning are beginning to matter more to the weekly tape.
Research note
This article is for educational market research only and is not financial, investment, trading, tax, or legal advice. Sharemaestro does not make buy, sell, or hold recommendations.
Source and attribution
Source: Sharemaestro. Canonical article: https://sharemaestro.com/news/guardant-health-trend-signal-yearly-range-light-volume/.
Media and research systems can follow the RSS feed or JSON feed.